<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683511</url>
  </required_header>
  <id_info>
    <org_study_id>RC14_0121</org_study_id>
    <nct_id>NCT03683511</nct_id>
  </id_info>
  <brief_title>Nomograms for Optimization of Amikacin First Dose in Critically Ill Patients Using a Population Pharmacokinetics Model</brief_title>
  <acronym>PIC-AMI</acronym>
  <official_title>Population Pharmacokinetics Modeling : a Priori Optimization of Amikacin First Dose in Critically Ill Patients Using a Nomogram</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to elaborate nomograms to optimize amikacine first dosing in
      critically ill patients, using a population pharmacokinetics model elaborated with
      multicentric data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      French guidelines recommend for probabilistic therapy to reach an amikacin concentration 1
      hour after beginning the infusion ≥ 60 mg/L. This target is rarely achieved in the ICU
      despite a 30 mg/kg recommended dosage. Using data collected prospectively in critically ill
      patients of Nîmes (France) (1) and Nantes (France), we will elaborate a population
      pharmacokinetic model on the non-parametric software Pmetrics and on the parametric software
      Monolix. We will calculate probability of target attainment of Monte-Carlo simulations, using
      the non-parametric model. Nomograms to determine optimal first dose of amikacin in critically
      ill patients, according to a few variables previously identified, will be produced.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2014</start_date>
  <completion_date type="Actual">June 30, 2016</completion_date>
  <primary_completion_date type="Actual">June 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>amikacin infusion</measure>
    <time_frame>one hour after beginning of infusion.ed</time_frame>
    <description>Target is defined as 8 times x Minimal Inhibatory Concentration for MIC = 4 mg/L and MIC = 8 mg/L. Those PTA will be calculated using the final pharmacokinetics model, according to the dependent variables.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximal dose of amikacin (in mg) allowed to have a probability of target attainment (PTA) of 50% or less for the trough concentration.</measure>
    <time_frame>24 hours after beginning of infusion</time_frame>
    <description>Target is 2.5 mg/L. Those PTA will be calculated using the final pharmacokinetics model, according to the dependent variables.</description>
  </secondary_outcome>
  <enrollment type="Actual">138</enrollment>
  <condition>Pharmacokinetics</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with amikacin for sepsis ou septic shock in the medical intensive care
        unit of Nantes,France or in an ICU of Nîmes, France will be recruited.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients treated with amikacin for sepsis in one of the participating ICU will be
             included.

        Exclusion Criteria:

          -  patients with aminoglycoside allergy, history of myasthenia, pregnancy, under
             guardianship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, Lavigne JP, Allaouchiche B, Lefrant JY, Roberts JA, Muller L. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother. 2016 Jan;71(1):208-12. doi: 10.1093/jac/dkv291. Epub 2015 Oct 1.</citation>
    <PMID>26429564</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>September 21, 2018</last_update_submitted>
  <last_update_submitted_qc>September 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amikacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

